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ABSTRACT
Pain management among pediatric patients with sickle cell disease continues to pose a challenge
to healthcare providers. Underlying disease processes, family perceptions of painful events, and
injury add to the complexity of effective pain management in this population. Sickle cell disease
is the most common variant of the many hemoglobinopathies in the world, with painful episodes
as the most common presentation to emergency departments for treatment beginning as
early as 6 to 8 months of age. Sickle cell pain crisis continues to receive less-than-effective pain
management treatment resulting in frequent hospitalizations, chronic pain, and increased
morbidity and mortality. This integrative review provides a synthesis of the published evidence
regarding the best approach to pharmacological management of pain during sickle cell pain crisis
in the pediatric population. Results of these studies strongly correlate pharmacological pain
management of pediatric sickle cell crisis pain on consensus and expert opinion with few strong
research studies conducted to completion. The literature also suggest new knowledge in the areas
of pathophysiology and pharmacogenomics in provider decisions in pharmacological
management of pediatric sickle cell crisis pain is not seen in clinical practice resulting in
undertreatment and repeated hospital admissions. The undertreatment of pediatric sickle cell
crisis pain contributes to morbidity and early mortality in this patient population.
Keywords: pediatrics, sickle cell pain crisis, pain management, pharmacogenomics
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PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL CRISIS PAIN
Sickle cell disease is an autosomal recessive inherited hemoglobinopathy, which occurs
in one in every 500 African American births (Raphael, Tran, Mueller, & Giardino, 2013). The
hallmarks of this disorder are sickling of erythrocytes, occlusion of small blood vessels, and
pain. These vaso-occlusive painful crises are debilitating and are medical emergencies (Morris et
al., 2013). Although 78% of 200,000 emergency room visits annually for patients with sickle cell
disease are for pain, 60% of those visits are among the pediatric population. Children with sickle
cell disease utilize healthcare services at a rate 8.8 times that of children in general, and have
increased hospitalizations and longer hospital stays than children with other chronic illnesses,
with an estimated average healthcare cost of approximately $1,354,000 during childhood (ages
0-21) (Raphael et al., 2013).
Many advances in the treatment of sickle cell disease have extended the life expectancy
from early childhood/young adulthood in the period 1950-1980, to a more recent range of 50 to
70 years in high-income countries such as the United States (Ballas, 2014). Sickle cell disease is
multifaceted, including neurological compromise, acute chest syndrome, sickle cell crisis pain,
and organ damage. Sickle cell crisis pain accounts for approximately 70% of all emergency
department visits for children with sickle cell disease (Fein, Avner, Scharbach, Manwani, &
Khine, 2017). Treatment of pediatric sickle cell pain crisis remains an area experiencing minimal
improvement toward effective management. Healthcare providers are beginning to research areas
of pain management utilizing a multimodal model to address the effective relief, intensity, and
frequency of pain symptoms among the pediatric population.
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This integrative review will provide a discussion of published literature related to
evidence-based pharmacological pain management strategies in the hospital setting for the
pediatric sickle cell patient experiencing a pain crisis. This review will contribute to the practice
of pain management of the pediatric sickle cell patient in pain crisis for the advance practice
nurse with improvement in the relief, intensity, and frequency of pediatric sickle cell pain crisis.
The focus of this integrative review is to analyze and synthesize the literature to present
evidence-based approaches to pharmacological management of pain during sickle cell pain crisis
in the hospitalized pediatric population.
Background
Pain and Pediatric Sickle Cell Disease
Understanding the mechanisms of pain in the sickle cell patient directs the effective
treatment and research into new treatment regimens in the relief of pain, decrease in pain
intensity, and pain frequency resulting in hospitalizations. Sickle cell pain crisis is defined by the
different types of pain and area of the nervous system impacted. Intermittent vaso-occlusive pain
crisis, defined by the lack of pain between episodes, is most common among the pediatric sickle
cell population. Because the dorsal horn is the main pathway to the central nervous system,
inhibiting and minimizing the transmission of painful stimuli begin here with pain relief efforts
by endogenous endorphins (Ballas, 2014). The second step is to control the transmission of
painful stimuli through the two sodium channel receptors, which determine the type, severity,
and duration of the vaso-occlusive pain crisis. These sodium channels, a-Amino-3-hydroxy5methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-Daspartic acid (NMDA) channels,
allow for effective relief of pain with non-opioids and opioids unless aberrant metabolism of
opioids exists for intermittent vaso-occlusive pain crisis (Ballas, 2014).
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Pain and Pharmacogenomics in Sickle Cell Disease
Pharmacogenomics has become a new field of research for improvement in pain
management among pediatric sickle cell pain crises. Understanding of the metabolic pathway
will assist healthcare practitioners in the development of individualized pain management
treatment plans to correct the undertreatment of pediatric sickle cell pain crisis. Traditionally
nonsteroidal anti-inflammatory drugs (NSAID) and opioids are the backbone of pain
management in children with sickle cell disease (Jaja, Patel, Scott, Gibson, & Kutlar, 2014; Yee
et al., 2013). Many African Americans and those of African descent are affected by genetic
variations in the CYP2D6 gene, which may contribute to poor metabolizing of opioid
medications requiring this pathway in obtaining pain relief (Yee et al., 2013). According to Jaja
et al. (2014), African American children with sickle cell disease have a slightly higher frequency
of the CYP2D6 gene deletions compared to healthy African Americans. Many pediatric patients
experience adverse reactions of narcotic administration, such as respiratory depression and
euphoria, without any analgesic effect (Yee et al., 2013). Notably, the CYP2C9 allelic variant
study showed 30% of children with at least one allele associated with reduced function in
metabolizing NSAIDS resulted in decreased analgesic effect and increased toxicity (Jaja et al.,
2014). Impaired NSAID metabolism is strongly associated with the following adverse effects
among children with sickle cell disease treated for sickle cell crisis pain: gastrointestinal
complications, renal impairment, fluid retention, and exacerbation of asthma (Jaja et al., 2014).
Understanding the metabolic pathway of the most commonly used medications in the treatment
of pediatric sickle cell crisis pain could potentially enable clinicians to identify patients with
impaired CYP2C9 metabolic capacity, enabling clinicians to make distinctions between a
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compliance problem and a metabolic defect, and tailor NSAID dosing accordingly to achieve
optimal analgesic response (Jaja et al., 2014).
At this time feasibility of genetic testing is not available; therefore, clinicians must use
clinical signs and symptoms of failed opioid and NSAID treatment of sickle cell pain crisis and
seek other adjuvants to obtain pain relief and decrease in pain intensity and pain frequency.

Opioid metabolic
pathway CYP2D6

NSAID metabolic
pathway CYP2C9

African American children with sickle
cell disease have a slightly higher
frequency of gene deletions.

30% of children with at least one allel
associated with reduced function in
metabolizing NSAIDS

Morphine clearan e is significantly
higher in individuals with sickle cell
disease compared to non-sickle cell
individuals.

Reduced function in metabolizing
NSAIDs results in decreased analgesic
effect and increased toxicity.

May experience adverse reactions of
narcotic administration without
analgesic effect

The following are NSAID adverse
effects among children with sickle
cell disease treated for sickle cell
crisis pain: gastrointestinal
complications, renal impairment,
fluid retention, and exacerbation of
asthma.

Figure 1. Effects of gene deletions and allelic variants in the opioid and NSAID metabolic
pathways. Adapted from Yee et al., 2013; Jaja et al., 2014.
Pharmacological Pain Management and Sickle Cell Pain Guidelines
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Many of the recommendations are based on weak evidence or recommendations related
to expert opinion, consensus, and studies from pain in children with cancer (National Heart,
Lung, and Blood Institute, 2014; World Health Organization, 2012). The World Health
Organization (WHO) guidelines use a 2-step approach to address pain in children with medical
illnesses based on strong recommendation with low quality of evidence (World Health
Organization, 2012). According to WHO, the first step is the treatment of mild pain with
paracetamol and ibuprofen. The second step is the treatment of moderate to severe pain utilizing
opioids, with morphine as the drug of choice. The WHO guidelines of 2012 do not recommend
the use of steroids in the treatment of pediatric sickle cell crisis pain or tramadol, due to a lack of
available evidence of effectiveness and safe use in children (World Health Organization, 2012).
These guidelines are not specific to sickle cell crisis pain but address this patient population in
the discussion. According to Sheely (2015), treatment of sickle cell crisis pain has poor levels of
evidence based on observational studies and expert opinion rather than clinical trials (Sheehy,
Finkle, Darbari, Guerrera, & Quezado, 2015). A multicenter research study has been undertaken
with a focus on the mechanism of sickle cell crisis pain with intravenous magnesium, as have a
few studies with oral magnesium to address the pathophysiology of sickle cell crisis pain in the
prevention of pain instead of treating sickle cell crisis pain in children (Badaki-Makun et al.,
2014).
Pharmacological Pain Management and Sickle Cell Pain Research Trials
The majority of pain research has been among cancer patients and adults. Gaps exist in
the literature on pain research specific to pediatric sickle cell patients. Effective management of
sickle cell crisis pain in children in the emergency department and hospital setting utilizes three
major classes of medications: opioids, non-opioids, and adjuvants (Hagedorn & Monico, 2016).
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Much of the research has focused on narcotic sparing interventions such as arginine, which is a
substrate of nitrous oxide production. Arginine is considered safe, inexpensive, and narcotic
sparing, which is important in the treatment of children with concerns for opioid metabolism as
an adjuvant in the treatment of pediatric pain crisis (Morris et al., 2013). Pain management
treatment for sickle cell patients who have failed typical pain management with opioids utilizes
ketamine, intranasal fentanyl, dexmedetomidine, gabapentin, and methadone for its analgesic
effect among the pediatric population. Ketamine infusion is viewed as an effective adjuvant in
the hospital setting in treating pediatric sickle cell pain and the safe monitoring and treatment of
any adverse reactions to this medication (Hagedorn & Monico, 2016).
Problem Statement
Noted as an accepted world health concern with associated morbidity and mortality, the
treatment of pediatric sickle cell pain crisis needs to be addressed among healthcare practitioners.
Improving quality of life, enhancing life expectancy, obtaining pain relief, and decreasing pain
intensity and frequency resulting in fewer emergency department visits and decreased length of
stay all outline the multimodal dynamics of pediatric sickle cell pain crisis. Pediatric sickle cell
pain crisis pain management continues to be undertreated and difficult to treat. According to
Ender et al. (2014), patients who reported high pain scores in sickle cell crisis pain historically
have increased risk of early death compared to patients who reported the lowest pain scores.
Improvement in the management of sickle cell crisis pain may help prevent hospitalizations,
morbidity, and mortality associated with sickle cell disease pain (Cacciotti, Vaiselbuh, &
Romanos-Sirakis, 2017; Lin, Strouse, Whiteman, Anders, & Stewart, 2016).
Purpose and Significance of the Scholarly Project
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The purpose of this scholarly project is to present evidenced-based pharmacological pain
management strategies in the care of sickle cell pain crisis within the pediatric population. The
management of pediatric sickle cell involves an understanding of its pathophysiology and
available treatment methodology available to healthcare providers. These strategies will advance
the practice of nursing in providing supportive care and symptom management, and improving
quality of life and life expectancy for children diagnosed with one of the world’s largest
hemoglobinopathies.
Sickle cell disease is the most common genetic hematological disorder in the United
States (U.S.). One in every 375 African-Americans is affected by sickle cell disease, with U.S.
estimates of 72,000 to 98,000 when corrected for early mortality (Lin et al., 2016). The leading
causes of mortality among people with the diagnosis of sickle cell disease include bacterial
infections from encapsulated organisms (38.4%), cerebral vascular accident (12.3%) with acute
pain crisis, and acute chest syndrome at 11%, with sickle cell pain crisis as the most common
presenting complication of this disease (Lin et al., 2016). Sickle cell pain crisis is associated with
increased risk of acute chest syndrome and mortality; thus, improvement in pain management
among children with sickle cell disease could help decrease acute chest syndrome and mortality
from sickle cell disease. The need exists for healthcare providers to do the following:
1. Understand the mechanism of sickle cell crisis pain, and the impact of undertreatment
of pediatric sickle cell pain crisis.
2. Provide evidence-based and expert opinion in the development of pain management
strategies and guidelines.
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Leading causes of mortality in sickle cell
disease

Bacterial infections

Cerebral vascular accident

Acute chest syndrome

Sickle cell crisis pain

Figure 2. Leading causes of mortality in sickle cell disease (Lin et al., 2016).
Clinical Questions
This integrative review will address the following clinical question: What is the best
pharmacological approach in the management of sickle cell pain crisis in the hospitalized
pediatric patient?
Questions to support and maintain focus of this review:
1. What evidence-based pain management strategies have been found to be safe and
effective in the management of sickle cell pain crisis in the hospitalized pediatric patient?
2. What best practices in pharmacological management support safe and effective treatment
of pediatric sickle cell crisis pain?
The goals of this project will be:
1. To provide a systematic integrative review of the literature related to pharmacological
pain management of pediatric sickle cell pain crisis.
2. To provide recommendations for the treatment of pain in the hospitalized pediatric sickle
cell pain crisis patient.
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Methods
Scientific reviews influence the definition of knowledge and clinical practice within the
healthcare environment. The conceptual framework developed by Harris Cooper (1982) was the
methodology used for this integrative review providing the rigor and validity needed in the
synthesis of evidence related to pharmacological pain management of pediatric sickle cell pain
crisis. This framework enables the project leader to provide evidence-based research findings,
guidelines, and reviews to healthcare practitioners in a concise report that highlights any bias,
limitations, need of further research, and practice implications (Cooper, 1982). An integrative
review is performed to explore the use of pharmacological treatment of sickle cell crisis pain
among children with sickle cell disease. The Liberty University Institutional Review Board
(IRB) application number 3189 was approved (see appendix D for approval letter). The focus of
this integrative review is to summarize past guidelines, reviews, and research of pharmacological
treatment of children with sickle cell crisis pain, presenting a current state of knowledge.
Framework
The framework for this scholarly project is rooted in the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) statement for reporting systematic reviews
and meta-analysis of studies that evaluate health care interventions (Liberati et al., 2009). The
foundational framework for the scholarly project is defined by Harris Cooper (1982). In addition,
the tool used for analyzing the literature is from the guidelines of Melnyk and Fineout-Overholt
(2011) for critiquing evidence.
PRISMA Statement
The purpose of the PRISMA system is to provide essential tools needed for summarizing
evidence accurately and reliably to assess the risk and benefits of a healthcare intervention. The
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PRISMA statement embraces a 27-item checklist and a four-phase flow diagram consisting of
identification, screening, eligibility, and inclusion of retrieved literature to provide consistency in
the process and documentation of reviews across all healthcare disciplines (see Appendix A for
PRISMA flow diagram). The essential items for reporting were based on the 27-item checklist to
ensure transparent reporting of systematic reviews, reducing the risk of flawed reporting of
systematic reviews.
Melnyk and Fineout-Overholt Critiquing Evidence
The tool used for analyzing the literature is from Melnyk and Fineout-Overholt’s (2011)
guidelines for critiquing evidence (Appendix C). The concept presented has a focus on viewing
the research for the contribution it can make to practice, instead of looking for study flaws in
determining inclusion as evidence during the appraisal process (Fineout-Overholt, Melnyk, &
Schultz, 2005). According to Fineout-Overholt, Melnyk, and Schultz (2005),
The purpose of critical appraisal is to determine the value of the research to practice by
answering the following questions: (1) Are the results of the study or systematic review
valid? (2) What are the results? (3) Are the findings clinically relevant to my practice? (p.
339)
The guideline discusses seven levels of evidence, with level 1 as the most rigorous, including
systematic reviews, randomized controlled trials, and guidelines based on systematic reviews or
meta-analysis, to level 7 for expert opinion. Case studies, cohorts, and qualitative studies are
described in the level of evidence table. An algorithm is used to guide the literature-critiquing
process, utilizing a step-wise flow to determine the level of evidence.
Cooper
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This scholarly activity is a rigorous process used to synthesize separate evidence-based
findings into a coherent whole (Cooper, 1982), providing a summary of the accumulated
scientific knowledge concerning the pharmacological treatment of sickle cell crisis pain, bringing
to the forefront research that was left unresolved. There are five phases to the integrative review
process: problem formation, data collection, evaluation of data points, data analysis and
interpretation, and presentation of results (Cooper, 1982). Each phase of the process addresses
threats to validity and ways to protect from threats to validity, enabling the project leader to
make fine distinctions between research study and review-based inferences providing optimal
criteria as practice guidelines. This process outlined by project leaders was closely followed to
decrease bias and inaccuracy, and to maintain academic rigor.
Problem Formulation Stage
This stage defines parameters and focus for the review process, clearly identifying the
problem and defining variables of interest. The problem addressed in this integrative review of
the literature is the best pharmacological approach in the management of pain during sickle cell
pain crisis in the pediatric population. Points of interest for the project include currently available
guidelines for pediatric sickle cell pain crisis, relevant pharmacological research in treatment of
pediatric sickle cell pain crisis, and factors contributing to the paucity of completed research
among children with sickle cell pain crisis. Other considerations of interest include factors
contributing to adherence or non-adherence to guidelines or protocols. According to Ballas
(2014), although there are many advances in the treatment of sickle cell disease, minimal
advances are noted in the management of pediatric sickle cell pain crisis. The World Health
Organization (WHO, 2012) and the National Heart, Lung, Blood Institute (NHLBI, 2014) reports
identified early initiation of analgesics in the relief of pain symptoms. Many of the guidelines are
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based on consensus and expert opinion due to the limiting factor of incomplete research trials
related to patients presenting in distress, hindering their ability to give consent/assent, according
to Nottage et al. (2016).
Data Collection Phase
The data collection stage of the review process involves identifying the population of
interest and relevant elements of inquiry (Cooper, 1982). The project leader has recognized that
one threat to validity is associated with retrieved studies not including all studies pertinent to the
topic of interest, the pharmacological pain management of sickle cell pain crisis in children.
Nevertheless, the project leader has utilized the online information retrieval technique, using key
words and phrases to obtain the maximum number of eligible studies.
Information Sources
Bibliographic databases, ancestry approach, and the Science of Social Science Citation
Indexes strategies were employed. The bibliographic search was performed using a
comprehensive, computer-assisted online search of EBSCO host, the Cumulative Index of
Nursing and Allied Health Literature (CINAHL), ProQuest, and Medline databases. The search
included dates from January 2012 to December 2017. The ancestry and Science of Social Science
Citation Indexes strategies were used to identify key studies within the search criteria dates. Key
terms used for the search include pediatric, sickle cell pain crisis, and pain management.
Boolean operators were used to refine and help focus the search (Holly, Salmond, & Saimbert,
2017). To determine the adequacy of the literature search strategies and to refine skills of the
project leader, a professional librarian was consulted.
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Eligibility Criteria
Defining eligibility criteria of the patient population, inclusion, and exclusion criteria
guided the data collection phase of this review. The pediatric patient population is defined as 0
years to 21 years, which will allow for generalizations among pediatric patients with sickle cell
pain crisis. The search of the literature included publications from January 1, 2012 to December
11, 2017, to obtain the most recent research and assess for areas of further inquiry. Criteria for
using publications included pharmacological intervention subject matter, full-text availability,
English-language reports, and U.S.-based research trials. Eligibility criteria for data collection
was supported by inclusion and exclusion criteria found in Table 2.
Literature Search Results
Utilizing EBSCO host, the Cumulative Index of Nursing and Allied Health Literature
(CINAHL), ProQuest, and Medline databases with inclusion dates from January 2012 to
December 2017, the search results identified 1,565 studies, guidelines, and reviews with no other
studies from other sources identified using the following key words: pediatrics, sickle cell pain
crisis, pain management. Of the 1,565 articles, 489 were duplicates. During the screening
process, the researcher reviewed summaries for the 1,076 studies, guidelines, and reviews
remaining after duplicates were extracted. Further review excluded 1,020 studies not meeting
established inclusion criteria, leaving 56 full-text studies to assess for eligibility. Continued
assessment resulted in the exclusion of 35 additional studies based on pre-set inclusion criteria,
leaving 21 studies, reviews, and guidelines for critical review. The critique and analysis of the 21
publications will be available in Tables 2-5.
Data Evaluation Stage
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During the data evaluation stage, data in the literature meeting criteria will undergo
critical judgment by the reviewer (Cooper, 1982). Primary and secondary sources were examined
and a determination made to evaluate if multifactorial contamination irrelevant to the problem of
interest had occurred (Cooper, 1982). Evaluation criteria were developed by the reviewer prior to
beginning the literature search, and only one reviewer was utilized during this process.
Data Analysis Stage
This stage of the integrative review process incorporated the synthesizing of the evidence
into a coherent statement about the research question (Cooper, 1982). A matrix in a table format
was used to organize, categorize, and summarize data according to the project clinical focus (see
Tables 2-5). The Nursing: Melnyk Pyramid (2011) I-VII leveling system was utilized in the
evaluation and analysis of the data sources (see Appendix C for Melnyk Pyramid). The sources’
theoretical information (pharmacological management of pediatric sickle cell crisis pain);
evaluation information including level of evidence and source; and methodological data (sample
size and setting) support for specific clinical questions were documented across studies
consistently. Records were kept during the data analysis process to ensure analytical integrity.
Data reduction. The reduction phase, which identified data according to subgroups to
promote effective management and maintain methodological rigor with the clinical question
guiding the focus, was performed in two sub-phases. First, subgroups classifications based on
level of evidenced were analyzed. The second sub-phase of reduction involved organization of
the extracted data into a manageable framework for display.
Data display. The extracted data were displayed within three matrices. Each matrix
represented an enhanced visualization of patterns across all data sources. In a visual format, each
matrix provides an organized record of relevant results for the literature (Holly et al., 2017).
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Data comparison. During the data comparison step of the integrative review patterns,
themes and relationships in the literature were identified. Diagrams displaying this visual
concept of the extracted data provided a visual systematic critical analysis and meaning of the
review findings. This visual diagram made the depiction of relationships, patterns, and themes
easier to capture.
Conclusion drawing and verification. According to Holly et al. (2017), findings from
the literature serve as data and appear as themes, metaphors, and key concepts that are developed
into succinct summaries of the findings. As commonalities and differences become apparent and
identified generalizations are formed, constructing a new comprehensive depiction of the subject
matter integrating all subgroups occurs during this process. Cooper (1982) stated the value of a
quantitative integrative review as follows: “The question is still open, and both sides will
probably revise their position before the debate is over” (p. 298).
Presentation of Results
Cooper (1982) described the translation of notes, printouts, and remembrances into a
public document as the presentation of the inquirer’s efforts to disseminate accumulated
knowledge to the scientific community. Data form the literature sources meeting inclusion
criteria were displayed and organized for ease of reader access to data points. To accomplish this
task, the DNP graduate employed the use of concept diagrams, tables, and flowcharts
accompanied by a narrative of the results. Tables were organized including level of evidence,
source, focus of literature source, conclusions, implication for practice, and recommendations.
Concept diagrams were used to illustrate the major themes, patterns, relationships, and
recommendations identified.
Evaluation Methods
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Results
There were 21 quantitative research articles included in the integrative review (see Table
1). The types of design included the following: two level-1 systematic reviews of randomized
control trials (Badaki-Makun et al., 2014; Brandow et al., 2016); seven level-2 randomized
control trials (Brousseau et al., 2015; Fein et al., 2017; Horst, Frei-Jones, Deych, & Shannon,
2016; Morris et al., 2013; Nottage et al., 2016; Jaja et al., 2014; Yee et al., 2013); one level-3
controlled trial with no randomization (Ender et al., 2014); three level-5 systematic reviews of
descriptive studies (Ballas, 2014; Hagedorn & Monico, 2016; Neri, Pestieau, & Darbari, 2013);
six level-6 descriptive observational designs (Cacciotti et al., 2017; Krishnamurti et al., 2014;
Lin et al., 2016; Raphael et al., 2013; Sheehy et al., 2015; Sheehy et al., 2017) and two level-7
expert opinions (National Heart, Lung, and Blood Institute, 2014; World Health Organization,
2012). Results of the integrative review receive further discussion using descriptive narratives
and diagrams of significant concepts.
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Pain and Pediatric Sickle Cell Disease
What should healthcare providers understand about the mechanism of sickle cell crisis
pain?
Four of the 21 studies discussed the mechanism, pathophysiology, and pharmacogenomics
of sickle cell crisis pain (Ballas, 2014; Jaja et al., 2014; Raphael et al., 2013; Yee et al., 2013).
These articles focus on two major pain pathways in the treatment of sickle cell crisis pain. The
first pathway allows travel of the pain stimuli to the central nervous system while sodium
channel receptors determine the type, intensity, and duration of sickle cell crisis pain. Healthcare
providers treating sickle cell crisis pain should administer parental opioid with frequent
reassessment of pain relief. Upon further evaluation of pain symptoms, combination therapy of
NSAIDS and adjuvants may be necessary, understanding the presence of hyperalgesia and
allodynia are symptoms of neuropathic pain. Informed clinicians are equipped to recognize
medication failure as a genetic variant and metabolic deficiency of ineffective pain management
and to administer effective medication and dosage in treating children with sickle cell crisis pain.
When considering pharmacological treatment of sickle cell crisis pain, opioids and
NSAIDs remain the backbone of treating pediatric sickle cell crisis pain in the hospital setting.
The field of pharmacogenomics assists the healthcare provider in identifying patients with
genetic variations of the CYP2D6 and CYP2C9 pathways contributing to poor pain response and
repeated failed emergency department management of pediatric sickle cell crisis pain. Among
African Americans, genetic variants of the CYP2D6 pathway for opioid metabolism are higher
among those with sickle cell disease. Healthcare providers should be aware that 30% of children
with sickle cell disease may also have a CYP2C9 genetic variant decreasing the analgesic effect
of NSAIDs, with an increase in adverse reactions. Understanding of the pathophysiologic
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mechanism and pharmacogenomics of management of children experiencing sickle cell crisis
pain has improved, although clinical management of sickle crisis pain does not reflect new
knowledge.

Figure 3. Flowchart of pain and pediatric sickle disease theme. Adapted from Ballas, 2014;
Nottage et all. 2016; Raphael, Tran, Mueller, and Giardino, 2013; Yee et al., 2013.
Pain Management and Pediatric Sickle Cell Pain Guidelines
What are the currently available guidelines in the treatment of pediatric sickle cell pain
crisis and barriers to healthcare providers?

25
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Four of the 21 studies discussed guidelines for the treatment of pain management of pain
in children with medical illnesses, sickle cell crisis pain, definitive reference for the use of
ketamine infusion, and developing clinical pathways in the treatment of children with sickle
crisis pain (Ender et al., 2014; Hagedorn & Monico, 2016; National Heart, Lung, Blood Institute,
2014; World Health Organization, 2012). These guidelines address time to initial dose of
medication, opioids as the drug of choice, reassessment intervals, incorporation of technology,
and intercollaborative teams. The nhlbi digital resource obtained data for a report based on
consensus from the American Pain Society. Of the nine pharmacological recommendations, only
one had high quality evidence and strong recommendation for rapid initiation of parental opioids
for the treatment of sickle cell crisis pain; two had low quality for treatment with NSAIDS for
mild pain if not contraindicated. The WHO developed a two-step approach in the pain
management of pain in children with medical illnesses, after removing codeine from the
analgesic ladder related to many poor metabolizers resulting in the ineffectiveness of pain relief
or ultra-metabolizers resulting in toxicity. This approach recommends NSAIDs for mild pain as
the first step, progressing to low-dose morphine for moderate pain, and increasing to standard
dosing of morphine for severe pain. The WHO standard of pain assessment is, upon arrival at
emergency department with administration of parental opioid, with 30 minutes of triage or 60
minutes of registration, and with subsequent pain assessment at 15-30-minute intervals until pain
is controlled, as reported by the patient. All the guidelines and reviews agree that morphine is an
essential medication in the treatment of sickle cell crisis pain. In patients with repeated failed
pain relief with opioids and NSAIDs, the addition of non-opioids and adjuvant may significantly
decrease pain scores.
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Managing pediatric sickle cell crisis pain is resource and time intensive. Only 9% of
pediatric-trained and 20% of adult-trained pediatric emergency department physicians report
following institutional protocols when treating sickle cell crisis pain (Cacciotti et al., 2017).
Many physicians cite two factors causing delays in the treatment of pediatric sickle cell crisis
pain:
1. Time required in reviewing patient chart;
2. Deciding the optimal pain management regimen.
No universal pediatric emergency department analgesic guidelines exist for the treatment of
sickle cell crisis pain (Cacciotti et al., 2017). The development of multidisciplinary clinical
pathways may promote the use of new knowledge in the clinical setting.
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Pediatric Sickle Cell Crisis Pain
Guidelines and Review

WHO 2-step analgesic ladder
-Parental opioids as drug of choice
for initial treatment
-Use of non-opioids and adjuvants
with failed response to opioids
-New knowledge of pain
management not used in clinical
practice
-Patient chart review and decisionmaking barriers to increase time to
initial medication administration

Figure 4. Flowchart of pediatric sickle cell crisis pain guideline themes. Adapted from Ender et
al., 2014; Hagedorn and Monico, 2016; National Heart, Lung, and Blood Institute, 2014; World
Health Organization, 2012.
Pain Management and Pediatric Sickle Cell Pain Research Trials
What identified evidence-based pain management strategies are found to be safe and
effective in the hospitalized pediatric sickle cell patients in pain crisis?
Prior research generally confirms morphine as the drug of choice in the initial treatment
of sickle cell crisis pain. Current research favors combination therapy of opioids and non-
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steroidal medication after an initial dose of parental opioids (Badaki-Makun et al., 2014;
Brandow et al., 2016; Brousseau et al., 2015; Cacciotti et al., 2017; Fein et al., 2017; Horst et al.,
2016; Morris et al., 2013; Neri et al., 2013; Nottage et al., 2016; Sheehy et al., 2015; Sheehy et
al., 2017). Since sickle cell crisis pain encompasses inflammatory, infarction, tissue damage, and
neuropathic pain, the combination therapy of opioids, NSAIDs, and adjuvants is used to optimize
pain management.
Further studies are entertaining combination therapies utilizing pathophysiology of sickle
cell crisis pain and receptors, reducing opioid tolerance and opioid induced hyperalgesia.
Medications not dependent on CYP2D6 pathways are needed for repeat failed opioid therapy
when aberrant genetics are present. Adjuvants such as arginine, ketamine, gabapentin, fentanyl,
dexmedetomidine, methadone, and magnesium are thought to be opioid reducing and safe in the
hospital setting, providing analgesia in the brain and spinal cord. The route of medication
administration affects the time to initial medication, and thus intranasal and subcutaneous routes
are explored since intravenous access poses a delay in beginning treatment.
What factors contribute to the paucity of literature in the treatment of pediatric sickle cell
pain crisis?
Much of the research in surrounding pediatric sickle cell crisis pain is hindered by the
inability to obtain adequate sample size to conduct research with generalizable results. The most
common limiting factor in completing research trials among this population relates to patients
presenting to the emergency department in distress, hindering their ability to give consent/assent.
Many research designs are shifting to obtaining consent/assent during routine clinic visits, in
order to increase participation for outcome analysis and clinical relevance.
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Pediatric Sickle Cell Crisis Pain
Research

*treat inflammation, infarction, and
tissue damage
*Opioids drug of choice
*combination therapy opioids and
non-steroidal
*intranasal and subcutaneous
medication routes obtain
consents/assent for research trials
during routine clinic visits
*utilization of pathways not dependent
on CYP2D6
*include neuropathic medications as
adjuvants

Figure 5. Flowchart of pediatric sickle cell crisis pain disease research themes. Adapted from
Badaki-Makun et al., 2014; Brandow et al., 2016; Brousseau et al., 2015; Cacciotti et al., 2017;
Fein et al., 2017; Horst et al., 2016; Morris et al., 2013; Neri et al., 2013; Nottage et al., 2016;
Sheehy et al., 2015; Sheehy et al., 2017.
Synthesis of Results
The many advances in the care of sickle cell disease have brought only minimal
improvements in the treatment of sickle cell crisis pain. The strength of the evidence was on both
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ends of the spectrum, with 12 studies on the high end and nine on the moderate-to-low end on
the Nursing: Melnyk Pyramid with a leveling system of I-VII. Three of the studies were reviews
of one multicenter trial on magnesium in the treatment of sickle cell crisis pain with the potential
to alter the pathophysiology of pain crisis. Many of the studies specific to pediatric sickle cell
crisis pain had small sample sizes, closed, or were still in progress after two years seeking to
obtain participants to continue the study. Many studies had small sample sizes and multicenter
studies were few. Results of these studies strongly correlate patient reports of sickle cell crisis
pain severity with increased risk of mortality. Many of the reviews are based on studies
conducted within cancer treatment of pain and perioperative pain management disciplines. Sickle
cell crisis pain is multidimensional and complex, including inflammatory, infarction, and tissue
damage with a profound effect on morbidity and mortality in the pediatric population. Three
major classes of medications—opioids, non-opioids, and adjuvants—are effectively used in the
treatment of pediatric sickle cell crisis pain.

Opioids

•morphine,fentanyl
•hydromorphine

Non-opioids

•nonsteriodal, anti-inflammatories
•acetaminophen,tramadol

Adjuvants

•antidepressants,benzodiazepines
•antihistamines,anticonvulsants

Figure 6. Flowchart of classes of safe and effective medications. Adapted from Hagedorn and
Monico, 2016.
Pediatric sickle cell crisis pain research continues to depend on consensus and expert
opinion with few strong research studies conducted to completion. The need to develop research
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protocols that remove barriers to conducting research to completion are drastically needed. The
lack of clinical guidelines utilizing new knowledge of the pathophysiology and
pharmacogenomics of sickle cell crisis pain has resulted in readmission of patients presenting
with the most common symptom of sickle cell disease.
Development of comprehensive emergency department guidelines with the participation
of pain management, anesthesia, pharmacy, and nursing may contribute to optimal and consistent
care (Badaki-Makun et al., 2014; Cacciotti et al., 2017).
Discussion
Summary of the Evidence
Research revealed the treatment of pediatric sickle cell crisis guidelines are based on few
evidenced-based studies with strong to moderate recommendations based on consensus and
expert opinion (National Heart, Lung, and Blood Institute, 2014; World Health Organization,
2012). The goal of this integrative review was to identify strong evidence-based studies in the
pharmacological treatment of pediatric sickle cell crisis pain to bring new knowledge to clinical
practice although there was strong consensus the research trials lacked sufficient numbers to
apply to the general population. Many of the studies addressed the clinical question but lacked
the rigor necessary to address pediatric sickle cell crisis pain management in a generalizable
setting. Two of the studies discussed developing clinical pathways and individual treatment plans
utilizing interdisciplinary teams and resource nurses to address the multifactorial needs of this
patient population, with the understanding that only 9% of pediatric-trained and 20% of adulttrained emergency department healthcare providers utilize these important tools in improving
patient outcomes (Cacciotti et al., 2017; Ender et al., 2014; Krishnamurti et al., 2014). Although
the 21 studies addressed pharmacological management of sickle cell crisis pain, three studies
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included new knowledge from pathophysiology and pharmacogenomics in their studies
(Brousseau et al., 2015; Jaja et al., 2014; Neri et al., 2013). Since mechanism-based strategies for
treating sickle cell crisis pain are sorely lacking, healthcare providers are reduced to treating the
symptom of pain (Sheehy et al., 2015).
Limitations
According to Cooper (1982), the five stages in the integrative review process are to
provide rigor and address threats in the review (Cooper, 1982). External bias of the studies
related to small sample size and single institution subjects was observed. Since inclusion criteria
were limited to U.S. studies, the strength of the evidence with combined studies was lacking.
Another limiting factor during the data evaluation stage was the use of one reviewer, who was
also the project leader.
Additional research is needed with larger sample sizes and multicenter involvement to
address the treatment of sickle cell crisis pain utilizing pathophysiology and pharmacogenomics
in the process. Research teams need to be more interdisciplinary and intercollaborative, including
all stakeholders to address this most debilitating problem in the lives of children with sickle cell
disease. The development of practice guidelines in other medical conditions has improved
clinical outcomes and patient satisfaction. This is an opportunity to build upon nursing science,
policy development, and applying new knowledge into clinical practice.
Conclusion
The undertreatment of sickle cell crisis pain is well known among healthcare providers
caring for children with sickle cell disease. The increased cost, hospitalizations, missed school
days, and decrease in life expectancy are not an option in the 21st-century healthcare
environment. This integrative review seeks to raise awareness of the old but continuing saga of
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undertreated pediatric sickle cell crisis pain and its effect on society, and its global impact.
Historically, patients who report high pain scores had increased risk of early death compared to
patients who report lower scores. Sickle cell disease is the most common of all inherited
hemoglobinopathies, with an average healthcare cost of $1,354,000 during childhood (ages 121). Clinical pathways for other pediatric diseases promote rapid stabilization, reduced hospital
admission rates, reduced inappropriate therapies and should be considered in addressing the
undertreatment of pediatric sickle cell crisis pain. Healthcare providers are in a position to affect
policy and practice changes to support clinical guidelines and research opportunities to address
this age-old concern. How long must children with sickle cell disease suffer from sickle cell
crisis pain? Healthcare providers must answer with a unanimous voice: “Not long.”
Implications for Practice
The most common presenting symptom of sickle cell disease to the emergency
department is sickle cell crisis pain in children, and it remains the most resource- and costintensive medical illness. There is a great need to develop guidelines to decrease pain frequency
and intensity based on high quality evidence-based research. The addition of information
technology with the ability to create reminders in medication administration to assist providers in
busy emergency departments and to allow easy access to protocols to facilitate decision making
regarding treatment regimens is desperately needed. Enhancing healthcare providers’ knowledge
of effective treatment strategies and new knowledge from pathophysiology and
pharmacogenomics is paramount in the care of children experiencing sickle cell crisis pain. The
development of point-of-care genomic testing for individuals with repeated pharmacological
failures is a valuable tool to direct effective evidence-based pain management in this patient
population.
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Research supports the use of opioids, non-opioids, non-steroidal pain relievers and
adjuvants in the treatment of sickle cell crisis pain with the introduction of intranasal and
subcutaneous routes when there is a delay in obtaining intravenous access. More research in the
study of medications addressing the pathophysiology of sickle cell crisis pain is needed, with
access to identifying repeat failures of opioid and NSAID treatment in this patient population.
Healthcare providers need to address the multidimensional elements in developing evidencedbased, individualized strategies in the treatment of pediatric sickle cell crisis pain in the hospital
setting.
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Pathophysiology of
sickle cell crisi pain

Pediatric
Sickle
cell crisis
pain

• Nociceptive Pain
• Neuropathic pain

Pharmocogenomics

Pharmocological
intervention
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• CYP2D6 Opioid Pathway
• CYP2C6 NSAID Pathway

• Opioids
• Non Opioids
• Adjuvants

Figure 7. Flowchart of multidimensional components in the treatment of pediatric sickle cell
crisis pain. Adapted from Ballas, 2014; Hagedorn and Monico, 2016; Jaja et al., 2014; Nottage et
all. 2016; Raphael et al., 2013; Yee et al., 2013;
Implications for Research
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The major impediment in the development of generalizable evidence-based safe and
effective pharmacological intervention of pediatric sickle cell crisis pain is study designs that
lack adequate sample size. The inability to obtain larger sample sizes and multicenter trials leads
to inferences and inappropriate treatment of children with sickle cell crisis pain. Obtaining
consent and assent during the time of patient distress has been inadequate, leading to minimal
participation. The development of study designs in which participation is discussed and
consent/assent obtained, with a method to identify participants upon arrival at the hospital
setting, has the potential of increasing participation when patient distress from sickle cell crisis
pain is not a factor in the decision.
Dissemination
The purpose of this integrative review of the pharmacological pain management of
pediatric sickle cell crisis pain was to provide a systematic review of separate evidence-based
findings in a format to define the state of knowledge. The public presentation of the summation
of accumulated knowledge concerning the pharmacological pain management of pediatric sickle
cell crisis pain will utilize the internal organization pain service and poster presentation at the
annual hospital nursing research symposium for 2019. Development of a manuscript for
publication in a professional nursing journal is in progress.

DNP ESSENTIALS
Essential I
The DNP scholarly project assisted in enhancing nursing knowledge in understanding the
impact of under-treatment of pediatric sickle cell pain crisis and the processes needed to affect
positive changes in the pain experience of such patients. The utilization of Essential I
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incorporated scientific knowledge and expert opinions from other sciences in collaboration with
nursing midrange theory of symptom management in decreasing the intensity, frequency, and
episodes of sickle cell pain crisis (Smith & Lieher, 2014). The integrative review, a form of
systematic review, is “the strongest level of evidence to guide intervention for clinical practice”
(Fineout-Overholt et al., 2005, p. 336) allowing nursing at the practice level to incorporate
evidence-based practice in the care of children with sickle cell pain crisis. The project
encourages discussion among stakeholders in collaboration across all entries into the healthcare
system in the effective management of sickle cell pain crisis in children. The DNP is positioned
to mentor nurses in the evidence-based practice process facilitating shorter intervals between
research, policy, and patient care.
Essential VIII
This prepares the DNP project leader to facilitate participation in evidence-based
management of pediatric sickle cell crisis pain among patients, families, nursing, and other
healthcare providers sustaining therapeutic relationships to facilitate improved patient outcomes
and satisfaction. Essential VIII focus on equipping DNP graduates in the mastery of
comprehensive, systematic health assessments designing, implementing, and evaluating
interventions based on nursing science and other sciences (American Association of Colleges of
Nursing, 2006). Children experiencing sickle cell crisis pain enter the healthcare system at a
variety of entry points of care and hours of operation, necessitating the need of effective
communication within the complex healthcare system. The project will give advance practice
nurses and nurses practicing in rural areas the knowledge needed to manage children
experiencing sickle cell pain crisis, using evidence-based guidelines to develop specific
treatment regimens according to resources, improving outcomes and providing quality patient
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care. The rigor of the integrative five-step review process by Harris Cooper (1982) assists in the
translation of research into practice and provides the framework to redesign effective and
realistic pain management strategies in the care of children with sickle cell crisis pain.
Continuing to analyze the research for the prevention of the pain cycle in this patient population
is crucial in reducing the risk of morbidity, mortality, and premature death in which the skills of
the DNP as a leader and mentor are much needed in advancing nursing practice and the nursing
profession.
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Table 1
Levels of Evidence for Project Literature Reference
Evidence category

Numeric level

Number of articles for
project

Systematic review & metaanalysis of randomized
controlled guidelines

1

2

One or more randomized
controlled trials

2

7

Controlled trial (no
randomization)

3

1

Case-control or cohort study
Systematic review of
descriptive & qualitative
studies

4
5

0
3

Single descriptive or
qualitative study

6

6

Expert opinion

7

1

Table 2
Inclusion and Exclusion Criteria

Inclusion criteria
Dates 2012 to 2017
Children ages 0 years to 21 years
Full text articles
Studies performed in the U.S.; Peer-reviewed
articles at all levels per Melnyk Levels of
Evidence (2015)
English language
Pharmacological pain management therapies

Exclusion criteria
Dates prior to 2012
Children older than 21 years
Abstract only articles
Studies outside of the U.S.

Non-English languages
Non-pharmacological, complementary, and
alternative therapies
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Table 3
Results Matrix for Pain and Pediatric Sickle Cell Disease
Focus of Article,
Author, and Year
Principles of vasoocclusive crisis
management and
pharmacogenomics of
opioids (Ballas, 2014)

Critique: Level of
Evidence and Source
Level 5: Systematic
review of descriptive
and qualitative studies

Pediatric Sickle Cell
Conclusions
Pain/Background
 Healthcare
 Opioids are the
providers’
most commonly
knowledge of
used analgesic in
sickle cell pain
the management of
management
sickle cell pain.
was suboptimal
 Gap between new
in the 1950’sadvances in
1970’s.
pathophysiology of
 Many people
pain,
with sickle cell
pharmacogenomics
disease died
of opioids, and the
during
clinical
childhood and
management of
young
sickle cell pain
adulthood.
 The
 Recent life
pathophysiologic
expectancy
mechanism of
ranges from
sickle cell vaso
50-70 years.
occlusive crisis
varies depending
 Chronic pain is
on the clinical
more common
presentation.
and severe.
 Specific analgesics
 Dorsal horn is
should be aligned
main pathway
with the specific
to central

Practice Implications and
Recommendations
 Understanding of
the
pathophysiologic
mechanism of pain
and
pharmacogenomics
of opioids has
improved
significantly.
 Clinical
management of
sickle cell pain
does not reflect
new knowledge.
Recommendations
 Determine
analgesics in
alignment with
specific
pathophysiologic
mechanism and
pharmacogenomics
of opioids.
 Clinical trials to
determine clinical
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nervous system
pain relief
efforts by the
endogenous
endorphins.
Two Na+
channels
receptors (aAmino-3hydroxy5methyl-4isoxazolepropi
onic acid
(AMPA) and
N-methylDaspartic acid
(NMDA)
which
determine the
type, severity,
and duration of
vaso-occlusive
pain crisis
The AMPA
and NMDA
allow for
effective pain
relief with nonopioids and
opioids unless
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pathophysiologic
mechanism and
pharmacogenomics
of opioids.

efficacy of opioids
and CYP genotypes
in patients with
sickle cell pain.
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The focus of this
study is to determine
the frequency of
CYP2C9 alleles and
genotypes in children
with sickle cell
disease in the U.S.
and African American
populations (Jaja et
al., 2014).

Level 2: Randomized
controlled trial



aberrant.
metabolism
exist
With the many
advances in
treating sickle
cell disease
minimal
advances in
management
sickle cell pain
are noted.
GI
complications,
renal
impairment,
fluid retention,
asthma
exacerbation
are some of the
adverse effects
associated with
impaired
NSAID
metabolism.
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Study showed 30%
of subjects with at
least one allele
associated with
reduced function in
metabolizing
NSAIDS.
Sickle cell disease
patients have a
slightly higher
frequency of the
CYP2D6 gene
deletions compared
to healthy African
Americans related
to opioid
conversion.
NSAIDs are the



Inform genomicbased drug
prescribing practice



The CYP2C9
variants play an
important role in
the analgesic effect
and toxicity of
NSAIDS.

Recommendations
 Preemptive
genotyping would
provide explanation
for those
individuals with
unsatisfactory drug
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backbone of pain
management of
children with sickle
cell disease.



The focus of this
study is to determine
the frequency of
CYP2D6 alleles and
genotypes in children

Level 2: Randomized
controlled trial



For codeine
and
hydrocodone
CYP2D6 is the
first step in the



Morphine clearance
is significantly
higher in patients
with sickle cell
disease compared



response or side
effects profiles
enabling clinicians
to make
distinctions
between a
compliance
problem and a
metabolic defect.
Future studies to
determine the
CYP2C9 profiles
of sickle cell
disease patients
that could
potentially enable
clinicians to
identify patients
with impaired
CYP2C9 metabolic
capacity and tailor
NSAIDs dosing
accordingly to
achieve optimal
analgesic response.
Sickle cell disease
patients may
require higher and
more frequent
opioid doses to
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with sickle cell
disease in the U.S.
and African American
populations (Yee et.
al, 2013).





pathway of
opioid
analgesic
effect,
converting the
prodrug to
morphine or
hydromorphon
e respectively.
CYP2D6
testing should
be considered
in patients with
repeated failed
outpatient pain
management.
Opioid
medications
such as
morphine or
hydromorphon
e that do not
require
enzymatic
activation may
produce better
analgesia in
this patient
population.
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to non-sickle cell
disease individuals.
Limitation includes
the inability to
identify less
common CYP2D6
alleles.





maintain adequate
analgesia.
Genetic variations
in the CYP2D6
gene may
contribute to poor
responses to
common pain
medications for
outpatient sickle
cell pain
management.
Personalized
medicine along
with genetic testing
will assist
clinicians to predict
response to
medications and
tailor treatmentsbased on genetic
polymorphisms.

Recommendations
 Larger studies of
CYP2D6
genotypes need to
be accomplished.
 Further study of the
extent of CYP2D6
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contribution to
failed outpatient
pain management
among sickle cell
disease in children

Determine whether
administrative data
have the capacity to
fully assess health
care utilization among
children with sickle
cell disease (Raphael,
2013).

Level 6: Single
descriptive study



The average
medical fee for
a child with
sickle cell
disease during
childhood ages
1-18 years is
approximately
1,354,000 U.S.
dollars.



Administrative
claims data
provided key
insights into the
scope of health
services use
including how and
where services are
being used and
highlights the
limitations of sole
reliance on
Medicaid record
reviews.



Despite progress in
the evaluation and
management of
sickle cell disease
care of affected
children, this
medical illness
continues to be a
high-cost and
resource-intensive
disease.

Recommendation
 Development of
guidelines to
decrease pain
frequency and
intensity
 Enhance provider
knowledge of
effective pain
treatment
modalities
 High quality
research

PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN

52
development to
provide evidencebased treatment
regimens
Development of
intercollaborative
teams with
appropriate
stakeholders



Table 4
Result Matrix Pain Management and Sickle Cell Pain Guidelines and Reviews
Focus of Article,
Author, and Year

Critique: Level of
Evidence and Source

The focus of this
article is to provide a
digital resource of the
treatment
recommendations
extracted from the full
report in the evidencebased treatment of
sickle cell disease
(National Heart, Lung,
Blood Institute, 2014).

Level 7: Expert panel

Sickle Cell Pain
Guidelines and
Reviews/Background
 Of the 17
recommendatio
ns, 9
recommendatio
ns are related to
the
pharmacologica
l treatment of
vaso-occlusive
pain, and 10
recommendatio
ns are related to

Conclusions


The range of
panel expert
consensus
included
initiation of
analgesic within
30 minutes of
triage or 60
minutes of
registration,
basing analgesic
use on pain

Practice Implications
and Recommendations




For severe pain,
consider
escalation of the
opioid dose by
25% until pain
control.
To prevent over
sedation, consider
the need of longacting opioids
with continuous
PCA opioid use.
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assessment,
hydration,
blood
transfusion,
oxygen therapy,
and nonpharmacologica
l treatment
Of the 9
pharmacologica
l
recommendatio
ns, a majority
of the evidence
was based on
consensus
consisting of
the American
pain society
with evidenced
reviewed by the
methodology
team of panel
of experts.
Of the 9
recommendatio
ns only 1 had
high-quality
evidence and
strong

53
assessment and
Recommendations
patient past use
 Use subcutaneous
of analgesic with
route of
relief of pain
medication
symptom.
administration
when intravenous
access is difficult.
 For severe pain,
reassess every 1530 minutes until
pain is under
control per patient
report.
 When using PCA
on demand
consider longacting opioids
 Do not use
meperidine unless
it is the only
effective opioid
for the individual.
 Gradual titration
of parenteral
opioids as sickle
cell disease crisis
pain resolves.
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recommendatio
n associated
with rapid
initiation of
parenteral
opioids for the
treatment of
sickle cell
disease crisis
pain.
2 low quality
evidences,
moderate
recommendatio
ns associated
with treatment
of NSAIDS for
mild to
moderate pain
in the absence
of
contraindication
s and around
the clock
continuous
infusion of
opioids
utilizing PCA
versus prn
administration
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The focus of this
Level 7: Expert panel
guideline is to provide
evidence-based
recommendations for
the treatment of pain
including opioids, nonopioids, and adjuvant
medications to improve
the management of
pain in children
experiencing pain
related to medical
diseases (World Health
Organization, 2012).







6
recommendatio
ns were of
consensus and
panel expertise.
Low quality of
evidence,
strong
recommendatio
n for strong
opioids as an
essential
medication in
the treatment of
sickle cell
disease pain
There is no
other class of
medication than
strong opioids
that is effective
in the treatment
of moderate to
severe sickle
cell disease
pain.
Acute pain is a
sudden onset
felt
immediately
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Development of
a 2-step
approach
incorporating
dosing at regular
intervals, using
appropriate route
of medication
administration,
and adapting
treatment to
individual child
2 step
approaches are a
revision of the 3step analgesic
ladder of 1986,
which
recommended
use of codeine as
a weak opioid
while the 2-step
approach
considers low
doses of strong







The effectiveness
of codeine is in
question related to
the percentage of
poor metabolizers
resulting in the
effectiveness of
this medication.
There is no
available evidence
of the comparative
effectiveness and
safety of
Tramadol in
children, no
license for
pediatric use in
several countries
and more research
needed.
Steroids
(corticosteroids)
and
bisphosphonates
(bone pain) are
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following
injury, severe in
intensity, arises
because of
tissue injury
stimulating
nociceptors and
generally
disappears
when injury
heals.
Sickle cell
disease pain is
generally
nociceptive
superficial and
deep somatic
visceral pain
arising from
internal organs,
bones, joints,
muscles,
connective
tissue, nose,
urethra, anus,
skin, and nose.
Sickle cell
disease arms,
legs, abdomen,
chest, and back
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opioids for the
treatment of
moderate pain
2-step strategy
strong
recommendation
with very low
quality of
evidence









not recommended
as adjuvants in the
treatment of sickle
cell disease pain
in children.
At the time of this
guideline not
possible to make
recommendations
because of limited
studies on the use
of gabapentin and
sub-anesthetic
dose of ketamine
Fear and lack of
knowledge are a
barrier to the
relief of pain
using opioids in
children.
The World Health
Organization
included
morphine as an
essential
medication in the
treatment of pain
in children.
No evidence
among children or
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pain generally
last 4-5 days.
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adults to
recommend
opioid rotation to
prevent side
effects of dose
escalation.
Recommendations
 Utilize 2-step
strategy in the
treatment of sickle
cell disease pain
in children.
 First step is the
treatment of mild
pain with
paracetamol and
ibuprofen, a
strong
recommendation
with low quality
evidence.
 Second step is the
treatment of
moderate to
severe pain with
morphine as the
drug of choice.
 Medication should
be administered at
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The focus of this
article is to provide a
definitive reference for
the use of ketamine
infusion for pain
management among
persons with sickle cell
pain (Hagedorn &
Monico, 2016).

Level 5: Systematic
review of descriptive and
qualitative studies





Sickle cell pain
effectively
managed in the
emergency
department and
hospital using 3
major classes of
medications:
opioids, nonopioids, and
adjuvants
Most common
opioids:
morphine,
hydromorphone
, and fentanyl.







regular intervals
using the
appropriate route
of administration,
adapting the
treatment to the
individual child.
Adjuvant
medicines may be
co-administered
with analgesic to
enhance pain
relief.

Ketamine
 Ketamine may be
infusion may
a useful adjuvant
provide adequate
with opioid when
pain relief for
high doses result
those who have
in no analgesic
failed the typical
effect.
pain
 Ketamine
management
infusions are to be
regimen.
performed in the
Ketamine
hospital setting
infusions used
where adverse
with opioids
reactions can be
managed.
reduce opioid
usage.
Recommendations
Adverse effects
 No specific
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Non-opioid
medications
include
nonsteroidal,
antiinflammatories,
acetaminophen,
and tramadol.
Adjuvant
medications
include
antidepressants,
benzodiazepine
s,
antihistamines,
and
anticonvulsants.
Nonpharmacologica
l therapies
include
psychological
evaluation;
occupational,
behavioral, and
cognitive
therapy;
acupuncture;
exercise;
massage; and
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were
hypertension,
unresponsivenes
s, nystagmus,
and dysphoria.



recommendations
can be made until
further studies are
performed using
Ketamine
infusions among
pediatric patients
with sickle cell
pain.
Ketamine
infusions may be
useful in treating
pediatric sickle
cell pain
refractory to other
standard
treatment.
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The focus of this
article is to determine
prospectively whether
a clinical pathway
improves the acute
management of sickle
cell disease vasoocclusive pain in the
pediatric emergency
department (Ender,
2014).

Level 3: Control trial, no
randomization







aqua therapy.
Inadequate
treatment of
pain is
associated with
fatal
complications
such as acute
chest syndrome.
Patients with
highest pain
scores have
historically had
increased risk
of early death
compared to
those with the
lowest pain
scores.
Clinical
pathways for
other pediatric
diseases than
sickle cell
disease have
shown to
promote more
rapid
stabilization,
decrease
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Clinical
 Clinical pathways
pathways can
in children with
improve
sickle cell disease
important
will need to
aspects of pain
address
management
multifactorial
such as time to
causes of pain and
first analgesic,
treatment
strategies.
time to first
opioid, increased
Recommendations
use of ketorolac.
 Further studies on
There was no
developing
significant
clinical pathways
change in pain
with
scores.
multidisciplinary
teams including
emergency
department
physicians,
hematology
physicians,
pharmacists,
nursing, and
patient/families.
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Individualized pain
management plans
developed because of
successful
implementation of a
standard protocol
jointly by the
emergency department
physician and primary
hematologist improve
patient satisfaction
with pain management
and reduce hospital
admissions as well as
readmission rates
(Krishnamurti, 2014).

Level 6: Single
descriptive study



hospital
admission rates,
and reduce the
use of
inappropriate
therapies.
Algorithm
emphasized
early initiation
of treatment
with
intravenous
morphine of
hydromorphone
with the goal of
obtaining
significant pain
relief within 1-2
hours of arrival
at the
emergency
department.
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Study
 Project compared
demonstrated
admission and
that detailed
readmission rates
individualized
within a week and
pain
average length of
management
hospital stay.
plans
 Reduction in
implemented in
length of hospital
collaboration
time served as an
between the
indicator of
patient,
effective pain
hematologist,
management in
and emergency
the emergency
department staff
department as
can improve
well as during
management of
hospitalizations.
sickle cell
associated vaso- Recommendations
 Each plan
occlusive crisis
included a list of
in the emergency
current home
department.
medications, other
medications,
analgesic dosage,
and frequency of
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Identify factors
associated with delays
in treatment of sickle
cell disease pain crisis
in the emergency
department with goal
of discerning whether
earlier pain
management is

Level 6: Single
descriptive study



The number of
people with
sickle cell
disease is
estimated to be
72,000 to
98,000 when
corrected for



Patient
experienced
significant
delays to initial
analgesic
medications.



administration for
emergency
department care
and inpatient pain
medication
regimen.
Sickle cell nurse
coordinator
visited each
patient during
weekday daytime
hours and
supported
emergency
department staff.
After hours
emergency
department staff
interacted with
hematology/oncol
ogy fellow on call.
A standardized
approach to pain
management may
improve
emergency
department
management of
sickle cell disease
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correlated with better
clinical outcomes (Lin,
2016).







early mortality.
Sickle cell
disease patients
have highest
pain scores of
all emergency
department
diagnosis, with
a mean score of
8.7 of 10.
Leading causes
of mortality
include
bacterial
infections from
encapsulated
organisms at
38%, cerebral
vascular
accidents at
12.3%, and
acute pain
episodes and
acute chest
syndrome at
11%.
Opioids are
most common
initial pain
medication
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pain crisis.
Improved pain
management may
help prevent
admissions from
sickle cell pain
and may decrease
acute chest
syndrome and
mortality from
sickle cell disease.

Recommendations
 Management of
severe pain
primarily with
opioids with
potential addition
from classes of
analgesics and
adjuvants
 Other classes of
analgesics include
NSAIDS, topical
agents,
corticosteroids.
 Adjuvants
including
antihistamines,
benzodiazepines,
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prescribed and
administered.
Second most
common
medications
prescribed and
administered
are NSAIDS,
most common
ketorolac as
initial therapy
with 60%
receiving
opioids.
9% of pediatric
emergency
department
physicians
report
following an
institutional
protocol when
treating pain
due to sickle
cell disease.
2 factors
causing delays
include time
required in
reviewing
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antidepressants,
anticonvulsants,
and
phenothiazines
may enhance the
analgesic potential
and ameliorate
potential adverse
effects.
Future use of
electronic
ordering system
alerting provider
when a patient
had not received
first medication
dose
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patient chart
and deciding
optimal pain
management
regimens.

Table 5
Results Matrix for Pain Management and Sickle Cell Pain Research Trials
Focus of Article,
Author, and Year

Critique: Level
of Evidence and
Source
Arginine as a safe
Level 2:
and inexpensive,
Randomized
and narcotic-sparing controlled trial
intervention in the
treatment of sickle
cell pain in children
(Morris, et, al.,
2013)

Research
Trials/Background






Arginine is an
obligate substrate for
nitrous oxide
production, and acute
deficiency is
associated with pain.
Single center,
prospective,
randomized, doubleblinded, placebocontrolled trial
38 patients ages 3-19
years with an average
age of 13.9 +/- 4 years

Conclusions






No significant
difference in length of
hospital stay between
arginine and placebo
group
54% reduction in
opioid use in the
arginine group during
hospitalization
Pain scores at
discharge in the
arginine group were
significantly lower
than the placebo
group.

Practice Implications
and Recommendations







No safety
concerns have
emerged with
arginine use.
Patients prefer IV
instead of oral
administration of
arginine.
Reduction in
opioid use by 54%
Beneficial adjunct
to standard
therapy

Recommendations
 Multicenter trial
with larger cohort
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Evaluate methadone Level 2:
pharmacokinetics in Randomized
children and adults
controlled trial
with sickle cell
disease with
secondary aim to
assess pain relief
and opioid
consumption (Horst,
2015).





Morphine is the
opioid most
commonly used to
treat pain associated
with sickle cell
disease and is the only
opioid with
previously defined
intravenous
pharmacokinetics in
children with sickle
cell disease.
Methadone may have
several therapeutic
advantages compared
with morphine,
including a more
rapid onset of effect,
longer elimination
half-life and duration
of effect, greater
bioavailability, and
absence of active
metabolites.
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Methadone produced
more pain relief than
standard care in
children with sickle
cell disease.
Higher plasma
concentrations of Smethadone and faster
systemic elimination
of S-methadone
comparable with
children receiving IV
methadone during
major surgery
Sickle cell disease
does not alter the
pharmacokinetics of
methadone in
children.
Pain relief scores at
baseline did not
differ, but pain relief
was significantly
greater at 12, 24, and



Multicenter trial
with cross-over
during
hospitalization



Morphine may not
be optimal choice
as it has an
increased
clearance and
shorter half-life in
patients with
sickle cell disease,
resulting in
increasing doses
to achieve
analgesia.
Morphine used in
sickle cell disease
has also been
associated with an
increased risk of
acute chest
syndrome
compared with
nalbuphine and a
slower onset of
pain relief
compared to other
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48 hours in children
receiving methadone.





opioids.
Previous
pharmacokinetics
of methadone
parameters can be
used to guide
dosing in children
with sickle cell
disease.
Methadone, a
NMDA receptor
agonist, may
reduce the
positive feedback
loop associated
with hyperalgesia.

Recommendations
 Further
evaluations of the
effectiveness and
safety of higher
initial IV dose of
methadone in
children with
sickle disease pain
Effects of
subanesthetic
Ketamine on pain
intensity and opioid

Level 6: Single
descriptive study





Chart review of
patients receiving
Ketamine infusions
Included pain





Ketamine infusions
safe in the hospital
setting
Best results in cancer



Use in the inpatient treatment
of cancer-related
pain
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2017)




Gabapentin in the
treatment of vasoocclusive
neuropathic pain
(Nottage, 2016)

Level 2:
Randomized
controlled trial





diagnosis of vaso
occlusive crisis and
sickle cell disease
230 patients and 360
separate hospital
admissions infusions
were eligible
Greater median
reductions in opioid
intake with sickle cell
patients and patients
with malignancyassociated pain

Research concentrated
on prevention of vasoocclusive crisis with
use of hemoglobin Finducing agents,
principally
hydroxyurea, little
effort toward
investigating
management of acute
pain crisis in children
Allodynia and
hyperalgesia are
common symptoms of
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pain
Study does not
examine effect on
chronic postsurgical
pain.
No control group for
this study and caution
needed in
generalizing results





No significant
psychotropic
effects and
hemodynamic
side effects
Possible
hypertension
during Ketamine
infusion may
require vasoactive
drugs.

Recommendations
 More clinical
trials with control
group


This trial is open and
started 2 years prior to
January 2016 and will
continue for 2 more
years. At the end it
will answer the
question regarding
gabapentin as an
effective home use in
conjunction with oral
opioids and nonopioids at the time of
pain onset, with the
goal of reducing the







Recognition that
pain is
nociceptive and
neuropathic
Concurrent use of
morphine and
gabapentin
provide better
analgesic at low
doses than singleagent therapy.
A single high dose
of gabapentin
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sickle cell pain and
defining
characteristics of
neuropathic pain.
Opioids act on µ
receptors, nonsteroidal drugs inhibit
cyclooxygenase, and
gabapentin-related
medications affect the
ά2δ subunit of the
voltage dependent
calcium channel.
Synergy of morphine
and gabapentin likely
result of actions on
peripheral and central
nervous systems
Sickle cell pain crisis
is the leading cause of
hospitalizations and
drivers of healthcare
expenditure in the
sickle cell population.
Pain is addressed
inadequately in most
clinical settings, and
current treatment
strategies are
unsatisfactory.
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need for acute visits
to the emergency
department and
hospitalizations for
vaso-occlusive pain
crisis.

decreases time
delays to first
request for
analgesia,
decrease pain
intensity, and
decrease opioid
consumption
Recommendations
 Limiting factor
for completing
research trials
among this patient
population related
to patient
presenting in
distress hindering
their ability to
give
consent/assent.
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To determine if
children with vasoocclusive pain crisis
who receive initial
treatment with
intranasal fentanyl
compared to
placebo achieve a
greater decrease in
pain score after 20
minutes (Fein,
2016)

Level 2:
Randomized
controlled trial



Drugs targeting
neuropathic pain have
not been studied
prospectively.



Pain accounts for
approximately 70% of
emergency
department visits for
children with sickle
cell disease.
Delay in obtaining
intravenous access in
children with sickle
cell disease is related
to scarring of veins
from frequent blood
draws and prior
episodes of
intravenous access.
20 minutes chosen
because it
corresponds to the
time after peak serum
concentration and the
known onset of
therapeutic effect of
intranasal fentanyl
and within the
National Heart Lung
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Greater decrease in
pain scores at 20
minutes after
administration of
intranasal fentanyl





Possible that
transmucosal
absorption of
intranasal fentanyl
is different in a
child with vasoocclusive pain
crisis related to
microvascular
congestion in the
nasal capillary
bed, resulting in
either less drug
being absorbed or
needing greater
time until drug
absorption, thus
prolonging the
time of
therapeutic effect
Intranasal fentanyl
may serve as a
noninvasive way
to bridge the gap
until intravenous
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Hospital case report
of 3 patients who
during vasoocclusive pain crisis
had severe pain
unresponsive to
opioids and
ketamine and were

Level 6: Single
descriptive study
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Blood institute
recommended
timeframe for
reassessment of pain
after analgesic
administration
Intranasal medications
are easily
administered; rapid
onset of action avoids
the gastrointestinal
tract and hepatic first
pass metabolism and
by-passes the brainblood barrier
specifically targeting
the central nervous
system.

Most approaches to
treat sickle cell
disease pain have
poor levels of
evidence, being based
on observational
studies and expert

access can be
obtained and
further parenteral
analgesics can be
administered.
Recommendations
 To not force
decision making
while under the
emotional duress
of a vasoocclusive pain
crisis, obtain
consent/assent by
pre-enrolling
during outpatient
hematology visit
separate from
pediatric
emergency
department visit.


Dexmedetomidine in
combination with
opioid and ketamine
is well tolerated and
temporarily associated
with reduction in
opioid requirements



Some sickle cell
disease patients
develop
pulmonary
hypertension,
which is a known
independent risk
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treated with
dexmedetomidine.
(Sheely, 2015)





Low dose ketamine
as an adjuvant to
opioids as a
therapeutic option

Level 5:
Systematic review
of descriptive and
qualitative studies
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opinions rather than
on clinical trials.
Providers mostly treat
symptoms because
mechanism-based
strategies for sickle
cell disease associated
pain are sorely
lacking.
Dexmedetomidine
without respiratory
depressant effect used
as sedative and/or
analgesic during
perioperative period
and intensive care
units

Ketamine is a nonbarbiturate
phencyclidine that
provides analgesia in

and improved pain
scores.


factor for
mortality.
Theoretical
concern for
vasoconstrictive
effect of
pulmonary
vasculature

Recommendations
 Trained registered
nurses to
administer
subanesthetic
doses of ketamine
providing
monitoring of
heart rate, oxygen,
and blood
pressure with
starting ketamine
dose of 0.1
mg/kg/hr. per
attending
physician
discretion.


Emerging data
suggest role of Nmethyl-D-aspartate
(NMDA) receptor in



Ketamine has an
inotropic action
and induces
vasoconstriction
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to manage
refractory sickle cell
disease related pain
(Neri, 2013)











Hypothesized that
the addition of
intravenous
magnesium to
standard therapy
would shorten

Level 2:
Randomized
controlled trial



the brain and spinal
cord.
Modulate opioid
tolerance and opioidinduced hyperalgesia
Low-dose ketamine
decreases heart rate
and blood pressure.
Low dose ketamine
used in the
management of acute
post-operative pain in
non-sickle cell disease
patients
Few studies evaluated
ketamine in sickle cell
disease patients.
Most studies included
small case review
numbers with
improved pain control
and decreased
morphine use after
addition of ketamine.
Several multicenter
trials in the setting of
sickle cell pain crisis
have been closed
because of inadequate
enrollment, making
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opioid tolerance and
opioid induced
hyperalgesia.



by inhibiting
nitrous oxide
production,
resulting in
increased heart
rate and blood
pressure.
Ketamine
increases
myocardial
oxygen demand.

Recommendations
 Studies with
larger numbers
evaluating
ketamine as
adjuvant to pain
management of
sickle cell disease
pain in children



Intravenous
magnesium did not
shorten length of stay,
reduce opioid use, or
improve quality of life
in children



Oral magnesium
used previously to
prevent pain crisis
with some
preliminary
success, but

PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN
hospital stay,
decrease opioid use,
improve healthrelated quality of
life for pediatric
patient hospitalized
with sickle cell
disease pain crisis
(Brousseau, 2015)









advancements in the
field difficult.
Magnesium is a
known vasodilator
with antiinflammatory effects
and has the potential
to alter the
pathophysiology of
pain crisis.
2 previous
intravenous
magnesium studies
single institution
trials. One showed
shortened length of
stay from 5 to 3 days
and a Canadian study
with no decrease in
length of stay.
Oral magnesium
studied in the
prevention of painful
crisis not the
treatment of acute
painful crisis
Main discharge
criterion was the
ability of the patient
to control pain with
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hospitalized for sickle
cell disease pain
crisis.

medication not
well tolerated
Recommendations
 Research trials
using oral
magnesium and
development of a
more tolerated
oral formulation
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Describe the
methods of the
intravenous
magnesium in sickle
cell vaso-occlusive
crisis in the
Magnesium for
Children in Crisis
(MAGiC) study and
discuss methods
used to overcome
barriers (BadakiMakun, 2014).

Level 1:
Systematic review
of randomized
controlled
guidelines







Adequate and
timely pain
management
improves quality of

Level 6: Single
descriptive or
qualitative study



oral opioids.
Sickle cell disease is
one of the most
common inherited
hemoglobinopathies
in the world.
Most of morbidity of
sickle cell disease is
due to recurrent vasoocclusive pain crisis
resulting in
hospitalizations and
effects on quality of
life.
Current management
based primarily on
expert opinion with
evidenced-based acute
management derived
from small and often
inadequate powered
sickle cell disease
specific studies or
studies of non-sickle
cell disease pain
Comprehensive
emergency
department guidelines
for assessment and
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Staff availability and
 In the U.S. 18,000
delay in initiation of
hospitalizations
study medication was
and 75,000
resolved by utilizing
hospital days are
the Pediatric
experienced
Emergency Care
annually of
Applied Research
children with
Network (PECARN)
sickle cell disease.
which provided in 28% of children
person emergency
with sickle cell
department coverage
disease admitted
and on-call coverage.
for vaso-occlusive
Protocol related
pain crisis are
factors resolved with
readmitted within
participation of other
30 days for
another crisis.
departments such as
pain management,
Recommendations
anesthesia, pharmacy,

nursing
Patient related factors
resolved with
consenting
patient/families
during routine care in
the hematology clinic
Patients who receive

combination treatment
were less likely to be
Recommendations
admitted from the
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life, and rapid
evaluation of pain is
critical to ensure
quick pain relief
and prevention of
complications
(Cacciotti, 2017).











treatment of sickle
cell disease pain and
may contribute to
optimal and consistent
care
Pediatric emergency
department analgesic
guidelines for sickle
cell disease pain are
not universal.
Pain description: mild
scale 1-3; moderate
scale 4-6; severe scale
7-10
Categories of
analgesics: narcoticsmorphine, Dilaudid,
Percocet, or
oxycodone
Non-steroidalibuprofen, ketorolac
CombinationNSAIDS and
narcotics
Sickle cell pain
encompasses both
inflammatory and
infarction and tissue
damage.
In the pediatric

76
emergency
department for further
pain management.







Improved pain
management may
help prevent
hospitalizations
and morbidity
associated with
sickle cell disease
pain.
Optimal
pharmacological
intervention
should aim at
targeting both the
inflammation and
tissue damage
components of the
pain to optimize
treatment.
Combination
therapy may
contribute to
optimizing pain
management in
the emergency
department.
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emergency
department 20% of
adult trained
physicians and 9% of
pediatric trained
physicians report
utilizing protocols
when managing sickle
cell related pain.
To determine if the
length of hospital
stay for an acute
sickle cell disease
pain event is
impacted by time to
initiation of first
intravenous narcotic
at presentation, total
initial dose of
opioids, and or time
to initiation of first
oral opioid
(Brandow, 2016)

Level 1:
Systematic review
of randomized
controlled
guidelines





Early initiation of oral
opioids facilitates
transition to home
pain management
regimen.
Higher initial dose of
opioids during early
management of pain
associated with
improved quality of
life scores at
discharge



Earlier initiation of
oral opioids in
patients hospitalized
with an acute sickle
cell disease painful
crisis strongly
associated with
shorter length of stay
and improved quality
of life at discharge



Early initiation of
oral opioid
therapy could
eventually lead to
standardization of
treatment
protocols for
sickle cell disease
pain.

Recommendations
 Collectively the
existing
postoperative data
and findings
provide rationale
for future
prospective trials
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regarding the
effectiveness of
early initiation of
oral opioids.

PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN

79

Appendix A

Identification

Flow Diagram

Records identified through
database searching
(n =1,565)

Additional records identified
through other sources
(n = 0)

Eligibility

Screening

Records after duplicates removed
(n =489)

Records screened
(n = 1,076)

Records excluded
(n =1,020)

Full-text articles assessed
for eligibility
(n =56)

Full-text articles excluded,
with reasons
(n = 35)

Included

Studies included in
qualitative synthesis
(n = 0)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 21)

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses:
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The PRISMA Statement. PloS Med 6(7): e1000097. Doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Appendix B
CITI Training Certificate
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